Clinical trials: Fatty Liver
Nonalcoholic Fatty Liver Disease
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.
- Trial name
- NCT02029586
- Testing
- MB12066 200mg
- Where
- 10 sites in South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Polycystic Ovarian Syndrome, Obesity
Post-Prandial Liver Glucose Metabolism in PCOS
The Investigators will measure if hepatic metabolism is upregulated in obese girls with PCOS and hepatic steatosis (HS), compared to PCOS without HS and obese controls without HS.
- Conditions
- Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
- Trial name
- PLUM (NCT03041129)
- Testing
- oral glucose tolerance test, MRI of liver
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males
1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2.
- Trial name
- NCT06308861
- Testing
- Single administration Amg dose Group, Single administration Bmg dose Group, Single administration Cmg dose Group
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Obesity, Weight Loss
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue.
- Conditions
- Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis
- Trial name
- NCT02933554
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Keith Pereira, MD:
Obesity, PreDiabetes
Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding.
- Conditions
- Obesity, PreDiabetes, Diabetes, Hypertension
- Trial name
- NCT05309057
- Testing
- Intermittent Fasting
- Where
- 2 sites in Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin…
- Conditions
- Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
- Trial name
- NCT04232566
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Insulin Resistance
Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.
The purpose of this study was to examine the pathophysiology of insulin resistance and the relation to the metabolic syndrome in humans.
- Trial name
- NCT02196051
- Testing
- one bout of 45 minutes exercise
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Yale University
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD
- Trial name
- NCT06176079
- Testing
- Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Michael Ohliger, MD PhD
Nonalcoholic Steatohepatitis (NASH)
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of IMM-H014 on fasted condition, and characterize PK of IMM-H014 on an empty stomach (fasted condition) and…
- Trial name
- NCT06216041
- Testing
- IMM-H014, IMM-H014 ( FE)
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Non-Alcoholic Fatty Liver Disease, Fat Soluble Vitamin Deficiencies and Disorders
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease
Excessive or insufficient levels of vitamins in the body can affect health. With the prevalence of obesity and MetS, NAFLD has become the leading cause of chronic liver disease and abnormal liver biochemical indicators in health…
- Trial name
- NCT06512701
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Metabolic Dysfunction-associated Fatty Liver Disease
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
- Trial name
- NCT06061640
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Fatty Liver
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy
Prospective determination of the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)in a primary care setting using ultrasound and percutaneous liver biopsy.
- Trial name
- NCT01100398
- Testing
- possible liver biopsy and serum collection
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Brooke Army Medical Center
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Fatty Liver, Bariatric Surgery Candidate
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
Omega-3 has been postulated to reduce hepatic steatosis by reducing lipogenic gene expression, exerting anti- inflammation action, reducing oxidative stress and improving glycemic control.
- Trial name
- OLIVER (NCT03972319)
- Testing
- 2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day
- Where
- Singapore
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Khoo Teck Puat Hospital
Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis
Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS)
Objective of the study Our working hypothesis is that platelets activated by gut-derived metabolites dock in the liver of NAFLD patients and amplify the inflammatory state by releasing pro-inflammatory cytokines/chemokines, which…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Control Condition
- Trial name
- NCT06623084
- Testing
- Platelets characterization
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Stefania Basili
Aging, Menopause
Gonadal Hormone, Gonadotropin and Cardiovascular Events
Deficiency in gonadal hormone has been considered to play a role in ageing related increased incidence of cardiovascular events. But the mechanism has not been fully elucidated.
- Trial name
- NCT02810821
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shandong Provincial Hospital
Nonalcoholic Steatohepatitis (NASH)
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
The Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Food Effect Study of HEC96719 in Healthy Subjects
- Trial name
- NCT04546984
- Testing
- HEC96719
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
NAFLD, NASH - Nonalcoholic Steatohepatitis
A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations
Liver disease (NAFLD) and (NASH) are a rapidly increasing population health threat driven primarily by diet and lifestyle. Fibrotic liver disease, culminating in cirrhosis, is frequently asymptomatic so it is common for a patient…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
- Trial name
- SUNN (NCT03726827)
- Testing
- Fibroscan screening
- Where
- United States
- Volunteers
- 1,006 people, healthy volunteers welcome
- Sponsor
- Fatty liver Foundation